Lirum Therapeutics, Inc. (LRTX)

Chart not available yet

Data will show when the stock starts trading on May 23, 2024.

Market Cap	101.97M
Revenue (ttm)	n/a
Net Income (ttm)	2.20M
Shares Out	9.27M
EPS (ttm)	0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About LRTX

Lirum Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Our lead product candidate, LX-101, is a novel, clinical stage, next generation, precision-engineered targeted therapy directed to the IGF-1R. The IGF-1/IGF-1R pathway has been implicated in a host of diseases. LX-101 has been clinically evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2024
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: LRTX

Financial Performance

Financial numbers in USD